Cella D - Search Results

1

Development and Initial Validation of the PROMIS®-Plus-HF Profile Measure.

Ahmad FS, Kallen MA, Schifferdecker KE, Carluzzo KL, Yount SE, Gelow JM, McCullough PA, Kimmel SE, Fisher ES, Cella D. Ahmad FS, et al. Among authors: cella d. Circ Heart Fail. 2019 Jun;12(6):e005751. doi: 10.1161/CIRCHEARTFAILURE.118.005751. Epub 2019 Jun 5. Circ Heart Fail. 2019. PMID: 31163985 Free PMC article.

2

The Functional Assessment of Cancer Therapy scale: development and validation of the general measure.

Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J, et al. Cella DF, et al. J Clin Oncol. 1993 Mar;11(3):570-9. doi: 10.1200/JCO.1993.11.3.570. J Clin Oncol. 1993. PMID: 8445433 Corrected and republished.

3

Methods and progress in assessing the quality of life effects of supportive care with erythropoietin therapy.

Yount S, Lai JS, Cella D. Yount S, et al. Among authors: cella d. Curr Opin Hematol. 2002 May;9(3):234-40. doi: 10.1097/00062752-200205000-00010. Curr Opin Hematol. 2002. PMID: 11953670 Review.

4

Assessment of patient-reported clinical outcome in pancreatic and other hepatobiliary cancers: the FACT Hepatobiliary Symptom Index.

Yount S, Cella D, Webster K, Heffernan N, Chang C, Odom L, van Gool R. Yount S, et al. Among authors: cella d. J Pain Symptom Manage. 2002 Jul;24(1):32-44. doi: 10.1016/s0885-3924(02)00422-0. J Pain Symptom Manage. 2002. PMID: 12183093 Free article.

5

Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: results from Eastern Cooperative Oncology Group Study 5592.

Eton DT, Fairclough DL, Cella D, Yount SE, Bonomi P, Johnson DH; Eastern Cooperative Oncology Group. Eton DT, et al. Among authors: cella d. J Clin Oncol. 2003 Apr 15;21(8):1536-43. doi: 10.1200/JCO.2003.07.128. J Clin Oncol. 2003. PMID: 12697878 Clinical Trial.

6

What are the most important symptom targets when treating advanced cancer? A survey of providers in the National Comprehensive Cancer Network (NCCN).

Cella D, Paul D, Yount S, Winn R, Chang CH, Banik D, Weeks J. Cella D, et al. Cancer Invest. 2003;21(4):526-35. doi: 10.1081/cnv-120022366. Cancer Invest. 2003. PMID: 14533442

7

Brief assessment of priority symptoms in hormone refractory prostate cancer: the FACT Advanced Prostate Symptom Index (FAPSI).

Yount S, Cella D, Banik D, Ashraf T, Shevrin D. Yount S, et al. Among authors: cella d. Health Qual Life Outcomes. 2003 Nov 21;1:69. doi: 10.1186/1477-7525-1-69. Health Qual Life Outcomes. 2003. PMID: 14633279 Free PMC article.

8

A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale.

Eton DT, Cella D, Yost KJ, Yount SE, Peterman AH, Neuberg DS, Sledge GW, Wood WC. Eton DT, et al. Among authors: cella d. J Clin Epidemiol. 2004 Sep;57(9):898-910. doi: 10.1016/j.jclinepi.2004.01.012. J Clin Epidemiol. 2004. PMID: 15504633

9

Validation of the Functional Assessment of Cancer Therapy-Breast Symptom Index (FBSI).

Yost KJ, Yount SE, Eton DT, Silberman C, Broughton-Heyes A, Cella D. Yost KJ, et al. Among authors: cella d. Breast Cancer Res Treat. 2005 Apr;90(3):295-8. doi: 10.1007/s10549-004-5024-3. Breast Cancer Res Treat. 2005. PMID: 15830143

10

Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis.

Cella D, Yount S, Sorensen M, Chartash E, Sengupta N, Grober J. Cella D, et al. J Rheumatol. 2005 May;32(5):811-9. J Rheumatol. 2005. PMID: 15868614

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,183 results

Search Page